StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
049960.KQ$16740.00-3.57%
Fair $16740.00+0.0%

049960.KQ

Cell Biotech Co., Ltd.

Unknown / UnknownKOSDAQ

$16740.00

-620.00 (-3.57%)

Fairly Valued+0.0%Fair Value $16740.00Fund rank 36/100 · Data gapFallback financials|
SA 52/C
F-Score: 6/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 24% · confianza 25%

FCF escenarios

weak_data · normalized FCF $7.9B · quality 73.7/100

Data gap 36/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 70/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

52/100

C

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific biotech pipeline model required: targets are disabled until product, probability, peak-sales and cash-runway data exists.
Thesis & Journal · 049960.KQLocal privado en este navegador · Cell Biotech Co., Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$114.6B

P/E

11.3x

↑

EV/EBITDA

6.6x

↓

ROE

7.7%

↑

Gross Margin

72.7%

↑

Debt/Equity

0.00

↓
52-Week Range$16740
$11350$18500

TradingView lightweight chart

049960.KQ price, volumen y niveles de valoración

Último $16,740Periodo +431.4%
Fair value: $16,740

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+1.7%

FCF CAGR

-8.0%

FCF margin

14.9%

FCF / Net income

0.78x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $53.13B · net income $10.13B · FCF $7.90B

2022-FY → 2025-FY

Gross margin

72.7%-2.4% pts

Operating margin

14.9%+2.9% pts

Net margin

19.1%+2.7% pts

FCF margin

14.9%-5.2% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$53.13B$53.13B$49.91B$53.79B$50.53B
Net Income$10.13B$10.13B$15.13B$6.30B$8.28B
EBITDA$14.90B$14.90B$19.54B$10.85B$13.85B
EPS1479.001479.002210.00921.001201.00
Gross Margin72.7%72.7%72.2%72.5%75.1%
Operating Margin14.9%14.9%13.6%4.1%12.0%
Net Margin19.1%19.1%30.3%11.7%16.4%
Balance Sheet
Debt/Equity0.000.000.010.010.01
Cash Flow
Free Cash Flow$7.90B$7.90B$17.99B$6.13B$10.14B
Returns
ROE7.7%7.7%12.2%5.6%7.7%
Valuation
P/E11.3211.326.4812.2110.66
EV/EBITDA6.576.574.836.525.83
P/B0.870.870.790.690.82
Growth & Yield
Revenue Growth6.4%6.4%-7.2%6.5%—
EPS Growth-33.1%-33.1%140.0%-23.3%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

0.1%

fácil

EPS terminal req.

$1485.40

Spread vs growth

-33.2%

5Y implied EPS CAGR

4.0%

fácil

EPS terminal req.

$1797.33

Spread vs growth

-37.1%

10Y implied EPS CAGR

6.9%

razonable

EPS terminal req.

$2894.62

Spread vs growth

-40.0%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +32.8%

Total return

+32.8%

Start / end P/E

5.7x → 11.3x

EPS bridge

2210.00 → 1479.00

Residual

-32.5%

EPS growth-33.1%
Multiple rerating+98.4%
Dividend+0.0%
Residual / FX / buybacks / cross-term-32.5%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.